Pharmacogenetic analysis of GLCCI1 in three north European pediatric asthma populations with a reported use of inhaled corticosteroids

Susanne J. H. Vijverberg; Roger Tavendale; Maarten Leusink; Leo Koenderman; Jan A. M. Raaijmakers; Dirkje S. Postma; Gerard H. Koppelman; Steve W. Turner; Somnath Mukhopadhyay; Colin N. A. Palmer; Anke Hilse Maitland-Van Der Zee

doi:10.2217/pgs.14.37

Pharmacogenetic analysis of GLCCI1 in three north European pediatric asthma populations with a reported use of inhaled corticosteroids

Susanne J. H. Vijverberg, Roger Tavendale, Maarten Leusink, Leo Koenderman, Jan A. M. Raaijmakers, Dirkje S. Postma, Gerard H. Koppelman, Steve W. Turner, Somnath Mukhopadhyay, Colin N. A. Palmer, Anke Hilse Maitland-Van Der Zee (Lead / Corresponding author)

Research output: Contribution to journal › Article › peer-review

21 Citations (Scopus)

Abstract

Background:GLCCI1 rs37972 has previously been associated with decreased lung function improvement upon treatment with inhaled corticosteroids (ICS) in asthmatics. Aim: To assess whether variation in rs37972 is associated with altered ICS efficacy in north European asthmatic children and young adults with a reported use of ICS. Patients & methods: rs37972 was genotyped in three cohort studies of asthmatic children with a reported use of ICS. As an indicator for asthma exacerbations, asthma-related hospital visits and oral corticosteroid use were studied. Asthma control was assessed using a questionnaire. Results: rs37972 T allele was not significantly associated with an increased risk of oral corticosteroid use (summary odds ratio: 1.20; 95% CI: 0.99-1.45), an increased risk of asthma-related hospital visits (summary odds ratio: 1.07; 95% CI: 0.89-1.29), uncontrolled symptoms (summary odds ratio: 1.01; 95% CI: 0.75-1.36) or higher ICS dosages (summary ß: 0.01, 95% CI:-0.06-0.08). Conclusion: Variation in GLCCI1 rs37972 genotype does not seem to affect ICS efficacy in north European asthmatic children.

Original language	English
Pages (from-to)	799-806
Number of pages	8
Journal	Pharmacogenomics
Volume	15
Issue number	6
DOIs	https://doi.org/10.2217/pgs.14.37
Publication status	Published - Apr 2014

Access to Document

10.2217/pgs.14.37

Cite this

Vijverberg, S. J. H., Tavendale, R., Leusink, M., Koenderman, L., Raaijmakers, J. A. M., Postma, D. S., Koppelman, G. H., Turner, S. W., Mukhopadhyay, S., Palmer, C. N. A., & Maitland-Van Der Zee, A. H. (2014). Pharmacogenetic analysis of GLCCI1 in three north European pediatric asthma populations with a reported use of inhaled corticosteroids. Pharmacogenomics, 15(6), 799-806. https://doi.org/10.2217/pgs.14.37

@article{12c01c91c743496ca55176a2dd36f94c,

title = "Pharmacogenetic analysis of GLCCI1 in three north European pediatric asthma populations with a reported use of inhaled corticosteroids",

abstract = "Background:GLCCI1 rs37972 has previously been associated with decreased lung function improvement upon treatment with inhaled corticosteroids (ICS) in asthmatics. Aim: To assess whether variation in rs37972 is associated with altered ICS efficacy in north European asthmatic children and young adults with a reported use of ICS. Patients & methods: rs37972 was genotyped in three cohort studies of asthmatic children with a reported use of ICS. As an indicator for asthma exacerbations, asthma-related hospital visits and oral corticosteroid use were studied. Asthma control was assessed using a questionnaire. Results: rs37972 T allele was not significantly associated with an increased risk of oral corticosteroid use (summary odds ratio: 1.20; 95% CI: 0.99-1.45), an increased risk of asthma-related hospital visits (summary odds ratio: 1.07; 95% CI: 0.89-1.29), uncontrolled symptoms (summary odds ratio: 1.01; 95% CI: 0.75-1.36) or higher ICS dosages (summary {\ss}: 0.01, 95% CI:-0.06-0.08). Conclusion: Variation in GLCCI1 rs37972 genotype does not seem to affect ICS efficacy in north European asthmatic children.",

author = "Vijverberg, {Susanne J. H.} and Roger Tavendale and Maarten Leusink and Leo Koenderman and Raaijmakers, {Jan A. M.} and Postma, {Dirkje S.} and Koppelman, {Gerard H.} and Turner, {Steve W.} and Somnath Mukhopadhyay and Palmer, {Colin N. A.} and {Maitland-Van Der Zee}, {Anke Hilse}",

year = "2014",

month = apr,

doi = "10.2217/pgs.14.37",

language = "English",

volume = "15",

pages = "799--806",

journal = "Pharmacogenomics",

issn = "1462-2416",

publisher = "Future Medicine",

number = "6",

}

Vijverberg, SJH, Tavendale, R, Leusink, M, Koenderman, L, Raaijmakers, JAM, Postma, DS, Koppelman, GH, Turner, SW, Mukhopadhyay, S, Palmer, CNA & Maitland-Van Der Zee, AH 2014, 'Pharmacogenetic analysis of GLCCI1 in three north European pediatric asthma populations with a reported use of inhaled corticosteroids', Pharmacogenomics, vol. 15, no. 6, pp. 799-806. https://doi.org/10.2217/pgs.14.37

TY - JOUR

T1 - Pharmacogenetic analysis of GLCCI1 in three north European pediatric asthma populations with a reported use of inhaled corticosteroids

AU - Vijverberg, Susanne J. H.

AU - Tavendale, Roger

AU - Leusink, Maarten

AU - Koenderman, Leo

AU - Raaijmakers, Jan A. M.

AU - Postma, Dirkje S.

AU - Koppelman, Gerard H.

AU - Turner, Steve W.

AU - Mukhopadhyay, Somnath

AU - Palmer, Colin N. A.

AU - Maitland-Van Der Zee, Anke Hilse

PY - 2014/4

Y1 - 2014/4

N2 - Background:GLCCI1 rs37972 has previously been associated with decreased lung function improvement upon treatment with inhaled corticosteroids (ICS) in asthmatics. Aim: To assess whether variation in rs37972 is associated with altered ICS efficacy in north European asthmatic children and young adults with a reported use of ICS. Patients & methods: rs37972 was genotyped in three cohort studies of asthmatic children with a reported use of ICS. As an indicator for asthma exacerbations, asthma-related hospital visits and oral corticosteroid use were studied. Asthma control was assessed using a questionnaire. Results: rs37972 T allele was not significantly associated with an increased risk of oral corticosteroid use (summary odds ratio: 1.20; 95% CI: 0.99-1.45), an increased risk of asthma-related hospital visits (summary odds ratio: 1.07; 95% CI: 0.89-1.29), uncontrolled symptoms (summary odds ratio: 1.01; 95% CI: 0.75-1.36) or higher ICS dosages (summary ß: 0.01, 95% CI:-0.06-0.08). Conclusion: Variation in GLCCI1 rs37972 genotype does not seem to affect ICS efficacy in north European asthmatic children.

AB - Background:GLCCI1 rs37972 has previously been associated with decreased lung function improvement upon treatment with inhaled corticosteroids (ICS) in asthmatics. Aim: To assess whether variation in rs37972 is associated with altered ICS efficacy in north European asthmatic children and young adults with a reported use of ICS. Patients & methods: rs37972 was genotyped in three cohort studies of asthmatic children with a reported use of ICS. As an indicator for asthma exacerbations, asthma-related hospital visits and oral corticosteroid use were studied. Asthma control was assessed using a questionnaire. Results: rs37972 T allele was not significantly associated with an increased risk of oral corticosteroid use (summary odds ratio: 1.20; 95% CI: 0.99-1.45), an increased risk of asthma-related hospital visits (summary odds ratio: 1.07; 95% CI: 0.89-1.29), uncontrolled symptoms (summary odds ratio: 1.01; 95% CI: 0.75-1.36) or higher ICS dosages (summary ß: 0.01, 95% CI:-0.06-0.08). Conclusion: Variation in GLCCI1 rs37972 genotype does not seem to affect ICS efficacy in north European asthmatic children.

UR - http://www.scopus.com/inward/record.url?scp=84901983744&partnerID=8YFLogxK

U2 - 10.2217/pgs.14.37

DO - 10.2217/pgs.14.37

M3 - Article

C2 - 24897287

AN - SCOPUS:84901983744

SN - 1462-2416

VL - 15

SP - 799

EP - 806

JO - Pharmacogenomics

JF - Pharmacogenomics

IS - 6

ER -

Pharmacogenetic analysis of GLCCI1 in three north European pediatric asthma populations with a reported use of inhaled corticosteroids

Abstract

Access to Document

Other files and links

Fingerprint

Cite this